Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031981 | 1.00 | TSHR (0.66) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL3618153 | 0.89 | TSHR (0.68) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL31079057 | 0.86 | TSHR (0.64) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL866071 | 0.86 | TSHR (0.64) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL31079023 | 0.86 | TSHR (0.64) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL6925841 | 0.85 | TSHR (0.63) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL19425510 | 0.83 | TSHR (0.61) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL2396473 | 0.81 | MAPT (0.50) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL19183403 | 0.80 | MAPT (0.49) | TSHRHTTMAPK1MAPTNPSR1 | |
| SCHEMBL29571318 | 0.79 | MAPT (0.46) | TSHRHTTMAPK1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
| WO-2008048540-A2 | 2-HYDROXY-2-PHENYL/THIOPHENYL PROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | SHBG, AR, FSHR | TSHR 401/4885HTT 327/4885MAPK1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.